Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19

Yayquier Díaz, View ORCID ProfileMayra Ramos-Suzarte, Yordanis Martín, Néstor Antonio Calderón, William Santiago, Orlando Viñet, O Yulieski La, Jorge Pérez, Augusto Oyarzábal, Yoan Pérez, Geidy Lorenzo, Meylan Cepeda, Danay Saavedra, Zaima Mazorra, Daymys Estevez, Patricia Lorenzo-Luaces, Carmen Valenzuela, Armando Caballero, Kalet Leon, Tania Crombet, Carlos Jorge Hidalgo
doi: https://doi.org/10.1101/2020.07.24.20153833
Yayquier Díaz
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayra Ramos-Suzarte
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mayra Ramos-Suzarte
  • For correspondence: mayra@cim.sld.cu
Yordanis Martín
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Néstor Antonio Calderón
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Santiago
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orlando Viñet
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O Yulieski La
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Pérez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Augusto Oyarzábal
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoan Pérez
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geidy Lorenzo
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meylan Cepeda
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danay Saavedra
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaima Mazorra
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daymys Estevez
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Lorenzo-Luaces
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Valenzuela
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armando Caballero
cArnaldo Milian Castro Universitary Hospital. Santa Clara, Villa Clara. Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalet Leon
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tania Crombet
bCenter of Molecular Immunology, Playa, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Jorge Hidalgo
aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of Coronavirus Disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which nineteen elderly residents were positive for SARS-CoV-2.

Methods Based on the increased susceptibility to viral-induced cytokine release syndrome inducing respiratory and systemic complications in this population, the patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody.

Results All the patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable and 18 out of 19 (94.7%) patients were discharged clinically recovered with negative RT-PCR at 13 days (median). One dose of itolizumab, circulating IL-6 decreased in the first 24-48 hours in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminary assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control subjects were well-matched regarding age, comorbidities and severity of the disease. Every three moderately ill patients treated with itolizumab, one admission in intensive care unit (ICU) was prevented.

Discussion/Conclusion Itolizumab was well tolerated. Its effect is associated with a reduction and controlling IL-6 serum levels. Moreover, treated patients had a favorable clinical outcome, considering their poor prognosis. This treatment is associated significantly with a decrease the risk to be admitted in ICU and reduced 10 times the risk of death. This study corroborates that the timely use of itolizumab, in combination with other antiviral and anticoagulant therapies, is associated with a reduction the COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19 and suggests its possible use in patients with cytokine release syndrome from other pathologies.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

RPCEC00000311 http://rpcec.sld.cu/trials/RPCEC00000311-Eg

Clinical Protocols

http://rpcec.sld.cu/trials/RPCEC00000311-Eg

Funding Statement

No founding supported was received for this research

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Clinical trial was approved by the ethics committee and by the Regulatory Agency for Medicines and Medical Equipment in Cuba (CECMED) on April 4, 2020

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript are available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 30, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
Yayquier Díaz, Mayra Ramos-Suzarte, Yordanis Martín, Néstor Antonio Calderón, William Santiago, Orlando Viñet, O Yulieski La, Jorge Pérez, Augusto Oyarzábal, Yoan Pérez, Geidy Lorenzo, Meylan Cepeda, Danay Saavedra, Zaima Mazorra, Daymys Estevez, Patricia Lorenzo-Luaces, Carmen Valenzuela, Armando Caballero, Kalet Leon, Tania Crombet, Carlos Jorge Hidalgo
medRxiv 2020.07.24.20153833; doi: https://doi.org/10.1101/2020.07.24.20153833
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
Yayquier Díaz, Mayra Ramos-Suzarte, Yordanis Martín, Néstor Antonio Calderón, William Santiago, Orlando Viñet, O Yulieski La, Jorge Pérez, Augusto Oyarzábal, Yoan Pérez, Geidy Lorenzo, Meylan Cepeda, Danay Saavedra, Zaima Mazorra, Daymys Estevez, Patricia Lorenzo-Luaces, Carmen Valenzuela, Armando Caballero, Kalet Leon, Tania Crombet, Carlos Jorge Hidalgo
medRxiv 2020.07.24.20153833; doi: https://doi.org/10.1101/2020.07.24.20153833

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)